Dr Abdul Mannan: Clonal Haematopoiesis – More Common, More Complex
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“Clonal Haematopoiesis: More Commoon. More Complex. More Relevant Than We Realised.
Today I shared an updated infographic on Clonal Haematopoiesis – a topic that has quietly moved from academic curiosity to something every clinician should have on their radar.
What struck me most while putting this together is how far beyond cancer this story goes.
For years, we framed CHIP and CCUS as “pre-leukaemic”. The problem is… that’s only half the picture.
These tiny clones behave like slow-burning fires.
They sit in the marrow, send out inflammatory signals, and nudge the immune system into a persistent “low-grade storm”. The result?
Higher rates of ischaemic heart disease, stroke, and heart failure, particularly with mutations like TET2, DNMT3A, JAK2 V617F.
And in the real world, that’s often where the danger lies.
The infographic breaks it down clearly:
- CHIP – mutation present, blood counts normal
- CCUS – mutation + sustained cytopenias
- High-risk CCUS – where leukaemic transformation risk climbs
- VEXAS – the perfect reminder that a “clonal process” doesn’t always behave like a cancer
It also highlights a simple monitoring approach that doesn’t overwhelm patients or clinics:
- CHIP → annual CBC
- CCUS → every 3–6 months
- High-risk patterns → consider marrow assessment and closer follow-up
As haematologists, we’re used to dealing with rapid, dramatic conditions.
Clonal haematopoiesis is the opposite.
Quiet. Slow. Easy to miss.
Until it isn’t.
If you’re teaching trainees, reviewing cardiology referrals, or running a general haematology clinic, this is a space worth understanding.
I’ll keep sharing more simplified, practical resources like this – to make the science accessible not just for exam preparation, but for real clinical decision-making.
Happy to discuss cases, interpretations, and grey areas.
The dialogue around this is just beginning.”
Follow the latest with Hemostasis Today.
-
Apr 26, 2026, 17:17Ajigbotosho Barakat: Leg Strength as a Key to Healthy Aging
-
Apr 26, 2026, 17:02Francisco Chacón-Lozsán: Limited Evidence Methylene Blue in Vasoplegic Shock
-
Apr 26, 2026, 16:57Gopal Patidar: Key Areas of Haemovigilance in ISBT Transfusion Today
-
Apr 26, 2026, 16:56Cathy Harrison: Oral Health in Older Adults Assessing the Impact of Ageing, Heart Failure, and Social Isolation
-
Apr 26, 2026, 15:08Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
-
Apr 26, 2026, 14:55Vanessa Simioni Faria: Precision Anticoagulation and Expanding Donor Frontiers
-
Apr 26, 2026, 14:52Flora Peyvandi: Results from the PROMISE Study Predicting Recurrent Stroke in Intracranial Atherosclerotic Stenosis
-
Apr 26, 2026, 14:40Rucha Patil: Key Scientific and Collaborative Moments at WFH 2026
-
Apr 26, 2026, 14:34Hadi Mohamad Abu Rasheed: Strengthening the Link Between Air Pollution and Cancer Prevention Through Global Collaboration